menu
    • menu
    [{"orgOrder":0,"company":"X-Chem","sponsor":"Orexia Limited","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Neurology","graph2":"Discovery","graph3":"X-Chem","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"X-Chem \/ Orexia Limited","highestDevelopmentStatusID":"2","companyTruncated":"X-Chem \/ Orexia Limited"},{"orgOrder":0,"company":"X-Chem","sponsor":"Excelra","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"","productType":"Small molecule","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Discovery","graph3":"X-Chem","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"X-Chem \/ X-Chem","highestDevelopmentStatusID":"2","companyTruncated":"X-Chem \/ X-Chem"},{"orgOrder":0,"company":"X-Chem","sponsor":"BioDuro","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"","productType":"Small molecule","year":"2022","type":"Partnership","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"X-Chem","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"X-Chem \/ BioDuro-Sundia","highestDevelopmentStatusID":"3","companyTruncated":"X-Chem \/ BioDuro-Sundia"},{"orgOrder":0,"company":"X-Chem","sponsor":"Sironax","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Undisclosed","year":"2023","type":"Partnership","leadProduct":"Undisclosed","moa":"","graph1":"Neurology","graph2":"Discovery","graph3":"X-Chem","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"X-Chem \/ X-Chem","highestDevelopmentStatusID":"2","companyTruncated":"X-Chem \/ X-Chem"},{"orgOrder":0,"company":"X-Chem","sponsor":"Kymera Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"","productType":"Small molecule","year":"2023","type":"Partnership","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"X-Chem","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"X-Chem \/ Kymera Therapeutics","highestDevelopmentStatusID":"3","companyTruncated":"X-Chem \/ Kymera Therapeutics"},{"orgOrder":0,"company":"X-Chem","sponsor":"Relay Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"","productType":"Small molecule","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"X-Chem","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"X-Chem \/ Relay Therapeutics","highestDevelopmentStatusID":"3","companyTruncated":"X-Chem \/ Relay Therapeutics"},{"orgOrder":0,"company":"X-Chem","sponsor":"Rumi Scientific","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"","productType":"Small molecule","year":"2023","type":"Partnership","leadProduct":"iBRD9","moa":"","graph1":"Genetic Disease","graph2":"Discovery Platform","graph3":"X-Chem","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"","sponsorNew":"X-Chem \/ X-Chem","highestDevelopmentStatusID":"3","companyTruncated":"X-Chem \/ X-Chem"},{"orgOrder":0,"company":"X-Chem","sponsor":"Evotec","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"","productType":"Small molecule","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"X-Chem","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"X-Chem \/ Evotec","highestDevelopmentStatusID":"14","companyTruncated":"X-Chem \/ Evotec"},{"orgOrder":0,"company":"X-Chem","sponsor":"Tonix Pharmaceuticals Holding Corp","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2024","type":"Collaboration","leadProduct":"TNX-4200","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"X-Chem","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"X-Chem \/ Tonix Pharmaceuticals Holding Corp","highestDevelopmentStatusID":"14","companyTruncated":"X-Chem \/ Tonix Pharmaceuticals Holding Corp"}]

    Find Clinical Drug Pipeline Developments & Deals by X-Chem

    Menu

    X-Chem

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            X-Chem

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            X-Chem

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : TNX-4200

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Preclinical

                            Sponsor : Tonix Pharmaceuticals Holding Corp

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Tonix And X-Chem Collaborate to Develop AI-Based Broad-Spectrum Antivirals

                            Details : The collaboration aims to accelerate the development of Tonix’s oral broad-spectrum antivirals, including TNX-4200, an oral broad-spectrum antiviral program.

                            Brand Name : TNX-4200

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            October 08, 2024

                            Lead Product(s) : TNX-4200

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Preclinical

                            Sponsor : Tonix Pharmaceuticals Holding Corp

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            X-Chem

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            X-Chem

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Technology

                            Study Phase : Discovery Platform

                            Sponsor : Evotec

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Evotec and X-Chem Collaborate to Accelerate Early-Stage Drug Discovery

                            Details : The collaboration aims to accelerate early-stage drug discovery by using X-Chem’s DEL technology which streamlines hit finding by simultaneously screening up to billions of DNA-tagged compounds.

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            September 05, 2024

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Technology

                            Highest Development Status : Discovery Platform

                            Sponsor : Evotec

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            X-Chem

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            X-Chem

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Technology

                            Study Phase : Discovery Platform

                            Sponsor : Relay Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            X-Chem Announces Achievement of Collaboration Milestone

                            Details : Under the collaboration, Relay Therapeutics utilized X-Chem’s DNA-Encoded Library platform to perform hit finding intended to discover molecules with differentiated pharmacological properties.

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            December 05, 2023

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Technology

                            Highest Development Status : Discovery Platform

                            Sponsor : Relay Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            X-Chem

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            X-Chem

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : iBRD9

                            Therapeutic Area : Genetic Disease

                            Study Phase : Discovery Platform

                            Recipient : Rumi Scientific

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Rumi Scientific Announces Partnership with X-Chem for Development of Lead Candidate in Huntington’s Disease

                            Details : Under the partnership, X-Chem will develop lead candidate, iBRD9, a BRD9 inhibitor, which is an epigenetic reader, as a novel therapeutic target for the treatment of Huntington’s Disease (HD).

                            Brand Name : iBRD9

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            December 05, 2023

                            Lead Product(s) : iBRD9

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Discovery Platform

                            Recipient : Rumi Scientific

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            X-Chem

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            X-Chem

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Technology

                            Study Phase : Discovery Platform

                            Sponsor : Kymera Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            X-Chem and Kymera Expand Existing Partnership

                            Details : The expanded partnership comprises 12 targets and grants Kymera exclusive rights to compounds discovered within the collaboration. X-Chem will apply its world-leading DEL platform to support Kymera’s discovery of small molecules and best-in-class prote...

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            January 31, 2023

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Technology

                            Highest Development Status : Discovery Platform

                            Sponsor : Kymera Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            X-Chem

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            X-Chem

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Neurology

                            Study Phase : Discovery

                            Recipient : Sironax

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            X-Chem and Sironax Begin Neurodegenerative Disease Drug Discovery Research Partnership

                            Details : X-Chem will screen its unique DNA-encoded libraries against difficult-to-drug targets implicated in neurodegenerative disease to discover hits. In turn, Sironax will prosecute these hits into transformational medicines for degenerative disease.

                            Brand Name : Undisclosed

                            Molecule Type : Undisclosed

                            Upfront Cash : Undisclosed

                            January 05, 2023

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Neurology

                            Highest Development Status : Discovery

                            Recipient : Sironax

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            X-Chem

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            X-Chem

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Technology

                            Study Phase : Discovery Platform

                            Sponsor : BioDuro

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            BioDuro-Sundia and X‑Chem Enter Partnership to Launch DEL Services in China for the Discovery of New Small M...

                            Details : Combined with BioDuro-Sundia’s one-stop drug discovery platform, customers can access world-class discovery technologies and support, covering hit identification and optimization, evaluation of lead and candidate compounds, and quickly advance to precl...

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            August 07, 2022

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Technology

                            Highest Development Status : Discovery Platform

                            Sponsor : BioDuro

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            X-Chem

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            X-Chem

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Technology

                            Study Phase : Discovery

                            Recipient : Excelra

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            X-Chem and Excelra's GOSTAR Join Forces to Advance Drug Discovery for Challenging Targets

                            Details : This synergistic new partnership between Excelra's GOSTAR and X-Chem's RosalindAI will enable to predict small molecules, chemical, biological, and physical properties, accelerating time and resource-intensive stages of drug discovery to preclinical cand...

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            February 09, 2022

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Technology

                            Highest Development Status : Discovery

                            Recipient : Excelra

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            X-Chem

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            X-Chem

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Neurology

                            Study Phase : Discovery

                            Sponsor : Orexia Limited

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            X-Chem Announces Achievement of Milestone In Orexia Collaboration

                            Details : After successfully reaching this development milestone in the collaboration, Orexia exercised an option to exclusively license the orexin receptor type 2 (OX2R) program from X-Chem, which comprises multiple novel OX2R-specific small molecule orexin posit...

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            July 22, 2020

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Neurology

                            Highest Development Status : Discovery

                            Sponsor : Orexia Limited

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth